Portfolio, Program, and Project Management in the Pharmaceutical and Biotechnology Industries

16.04.2010

Englisch

9780470049662

John Wiley & Sons

Nein

352

Gebundene Ausgabe

Klebebindung

Pete Harpum is a Director of Harpum Consulting and has been consulting on Portfolio, Program, and Project Management (P3M) for some ten years. He chairs and contributes to many conferences and symposiums on P3M. Mr. Harpum's other activities include postgraduate lecturing and research on P3M for three world-class universities, and supporting the Association for Project Management, Project Management Institute, and the Drug Information Association in various ways.

Biotechnologische Industrie, Chemical Engineering, Chemie, Chemische Verfahrenstechnik, Chemistry, Drug Discovery & Development, Industrial Engineering, Industrial Engineering / Project Management, Industrielle Verfahrenstechnik, Pharmazeutische Industrie, Process Development, Projektmanagement i. d. Industriellen Verfahrenstechnik, Verfahrensentwicklung, Wirkstoffforschung u. -entwicklung

PNB - Medizinische Chemie, Pharmazeutische Chemie

List of Contributors. Acknowledgements. Introduction. SECTION I. The Life Science Industry Context for Portfolio, Program, and Project Management. Introduction. 1 A Review of Project Management in Life Science Industry Sectors (Thomas R. Dunson). 2 The Impact of Organizational Size on Drug Project Management (Eric Morfin). 3 Drug Development in Biotech and How We Can Do It Better (Susan Linna). SECTION II. The Portfolio, Program, and Project Management Approaches and Processes. Introduction. 4 An Overview of the Organization and Processes of Portfolio, Program and Project Management (Pete Harpum). 5 Portfolio Management in the Pharmaceutical Industry: Balancing Corporate Need with the Reality of Delivering Products to the Market (John Bennett). 6 Program Management in Drug Development (Pauline Stewart-Long). 7 Project Control (Martin Powell). 8 Managing Uncertainty in Drug Projects (Pete Harpum and Thomas R. Dunson). 9 Managing Drug Safety Risk (Thomas R. Dunson and Eric Morfin). 10 Developing Program Strategy (Pete Harpum). 11 Project Value Management: Ensuring the Development of Added Value Drug Products (Trevor Brown and Stephen Allport). SECTION III. Integrating the Processes. Introduction. 12 Integrated Business Process to Support Cross-Functional Drug Development (Martin D. Hynes III). 13 Integrated Drug Development From Cradle to Grave and From Lab to Market (Stephen Allport and Terry Cook-Davies). 14 The Development of P3M Capability in Drug Development Organizations (John Arrowsmith, Patrick Grogan and Bob Moore). 15 Implementing Portfolio, Program, and Project Management Best Practices in Drug Development Organizations (Pete Harpum, Ashley Jamieson and Inge Fisher). Bibliography.

239 mm

16.4 cm